Skip to main content

Non-Small Cell Lung Cancer Clinical Trials

Review the non-small cell lung cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 351-375 of 460

Evaluation of AP-002 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Status: Active
Location: University of California San Francisco, San Francisco, California
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating MM-310 in Patients With Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of PSB205 in Subjects With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of BND-35 in Participants With Advanced Solid Tumors
Status: Active
Location: University of Colorado, Denver, Colorado
Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial
Status: Enrolling by Invitation
Location: 3 locations
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Status: Enrolling by Invitation
Location: 3 locations
Photoimmunotherapy with ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Status: Approved
Location: Roswell Park Cancer Institute, Buffalo, New York
Lorlatinib plus Local Consolidation Therapy for the Treatment of ALK Positive Stage IV Non-small Cell Lung Cancer
Status: Approved
Location: M D Anderson Cancer Center, Houston, Texas
Personalized Vaccine (PANDA-VAC) and Pembrolizumab for the Treatment of Squamous Cell Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Status: Approved
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy with or without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients who are PD-L1 Negative
Status: Temporarily Closed to Accrual
Location: 156 locations
Stereotactic Body Radiation Therapy with or without Nivolumab in Treating Patients with Stage I-IIA or Recurrent Non-small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: 4 locations
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Status: Temporarily Closed to Accrual
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Bemcentinib and Pacritinib for Treating Patients with Locally Advanced and/or Metastatic, Recurrent or Refractory Lung Cancer
Status: Temporarily Closed to Accrual
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
KSQ-001EX for the Treatment of Patients with Advanced or Metastatic Melanoma, Recurrent Non-Small Cell Lung Carcinoma or Advanced Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy with or without AGuIX for the Treatment of Central Lung Tumors and Locally Advanced Pancreatic Ductal Adenocarcinoma
Status: Temporarily Closed to Accrual
Location: 2 locations
Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care
Status: Temporarily Closed to Accrual
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania